<DOC>
	<DOCNO>NCT02011269</DOCNO>
	<brief_summary>This randomize , blind , multicenter study assess safety treatment effect 12 week Trichuris suis ova subject diagnose moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>TSO Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Males female , 18 75 year old . Diagnosis stable plaque type psoriasis least 6 month prior baseline Baseline moderate severe psoriasis , define follow : 1 . Psoriasis cover body surface area ( BSA ) ≥ 10 % , ; 2 . PGA ≥ 3 , ; 3 . PASI ≥ 12 Patients currently take take past 30 day , reason , medication , opinion investigator , suppress immune response . This may include limited systemic steroid , azathioprine , methotrexate , cyclosporine , FK506 , mycophenolate mofetil , mycophenolic acid , etanercept , adalimumab , infliximab , ustekinumab , cimzia , biologic agent target cell cytokine immune system . Patients inhaled ophthalmic steroid allow . Patients demonstrate primary lack response one follow biologic agent : etanercept , adalimumab , infliximab ustekinumab . Patients initially respond one agent subsequently lose response ( secondary lack response ) eligible study entry ; however , secondary lack response one agent exclude patient study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>TSO</keyword>
	<keyword>Ova</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>plaque-type</keyword>
	<keyword>Coronado</keyword>
	<keyword>Moderate severe plaque psoriasis</keyword>
</DOC>